Photo of Erman Akkus taken from mn.uio.no
Apr 16, 2024, 10:57
Erman Akkus: 2 studies from JAMA and Thyroid Journal
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:
1.” Second primary breast cancer among young (≤40 yr) stage 0-III breast cancer survivors: a study of JAMA.
At median 10 years:
- 2.2% for women who did not carry a germline pathogenic variant;
- 8.9% for carriers of a pathogenic variant;
- PV (pathogenic variant) carriers vs non carriers sHR (sub-hazard ratio): 5.27( 1.43-19.43).
Importance of germ line genetic testing in young women with breast cancer!”
Source: Erman Akkus/X
2. ”Pembrolizumabin addition to Dabrafenib/Trametinib for BRAFV600E-mutated anaplastic thyroid carcinoma: a study by Thyroid Journal.
Pembrolizumab added upfront or at progression vs dabra-trame alone:
- mOS: 17 vs 9 mo, p=0.03
- mPFS: 11 vs 4 mo, p=0.04
If dabra-trame given as neoadjuvant (before surgery), mOS: 63 mo.”
Source: Erman Akkus/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19
Dec 21, 2024, 19:18
Dec 21, 2024, 18:59
Dec 21, 2024, 18:57
Dec 21, 2024, 18:54